Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in New York City:

• Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5, 2024, at 1:50pm ET
• Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45pm ET
• H.C. Wainwright 26th Annual Global Investment Conference: Corporate presentation on Wednesday, September 11, 2024, at 8:30am ET

A live webcast of each conference event can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the events.

About Amylyx Pharmaceuticals

Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal diseases. The Company has preclinical or clinical development programs underway in neurodegenerative, neuroendocrine, and endocrine diseases. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered in Cambridge, Massachusetts. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.